ABCB1, which is known to be responsible for drug resistance in chronic myeloid leukemia (CML), decreases in expression levels after treating with β-catenin and Wnt1 shRNA [18]. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.